Frontiers in nephrology最新文献

筛选
英文 中文
Editorial: Insights in glomerular disease.
Frontiers in nephrology Pub Date : 2024-12-12 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1480968
Bryan Chang, Abbal Koirala, Duvuru Geetha
{"title":"Editorial: Insights in glomerular disease.","authors":"Bryan Chang, Abbal Koirala, Duvuru Geetha","doi":"10.3389/fneph.2024.1480968","DOIUrl":"10.3389/fneph.2024.1480968","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1480968"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage.
Frontiers in nephrology Pub Date : 2024-12-03 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1455321
Bernard Canaud, Peter Stenvinkel, Rebecca Scheiwe, Sonja Steppan, Sudhir Bowry, Giuseppe Castellano
{"title":"The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage.","authors":"Bernard Canaud, Peter Stenvinkel, Rebecca Scheiwe, Sonja Steppan, Sudhir Bowry, Giuseppe Castellano","doi":"10.3389/fneph.2024.1455321","DOIUrl":"10.3389/fneph.2024.1455321","url":null,"abstract":"<p><p>In hemodialysis (HD), complement activation, bioincompatibility, and inflammation are intricately intertwined. In the 1970s, as HD became a routine therapy, the observation of complement pathway activation and transient leukopenia by cellulosic dialysis membranes triggered the bioincompatibility debate and its clinical relevance. Extensive deliberations have covered definitions, assessment markers, scope, and long-term clinical consequences of membrane-dependent bioincompatibility reactions. While complement pathways' interplay with coagulation and inflammation has been delineated, HD's focus has primarily been on developing more biocompatible membranes using advanced technologies. Recent advances and understanding of the current HD delivery mode (4-hour sessions, thrice weekly) suggest that factors beyond membrane characteristics play a significant role, and a more complex, multifactorial picture of bioincompatibility is emerging. Chronic activation of the complement system and persistent low-grade \"uremic inflammation\" in chronic kidney disease (CKD) and HD lead to premature inflammaging of the kidney, resembling aging in the general population. Cellular senescence, modulated by complement activation and the uremic milieu, contributes to chronic inflammaging. Additionally, the formation of neutrophil extracellular traps (NETs, process of NETosis) during HD and their biological activity in the interdialytic period can lead to dialysis-induced systemic stress. Thus, complement-inflammation manifestations in HD therapies extend beyond traditional membrane-related bioincompatibility consequences. Recent scientific knowledge is reshaping strategies to mitigate detrimental consequences of bioincompatibility, both technologically and in HD therapy delivery modes, to improve dialysis patient outcomes.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1455321"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.
Frontiers in nephrology Pub Date : 2024-11-27 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1488758
Thomas S van Lieshout, Anastasia K Klerks, Osman Mahic, Robin W M Vernooij, Michele F Eisenga, Brigit C van Jaarsveld, Alferso C Abrahams
{"title":"Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.","authors":"Thomas S van Lieshout, Anastasia K Klerks, Osman Mahic, Robin W M Vernooij, Michele F Eisenga, Brigit C van Jaarsveld, Alferso C Abrahams","doi":"10.3389/fneph.2024.1488758","DOIUrl":"10.3389/fneph.2024.1488758","url":null,"abstract":"<p><strong>Background: </strong>Patients with kidney failure undergoing dialysis often suffer from anemia. Iron deficiency, along with a shortage in erythropoietin, is a common cause. Peritoneal dialysis (PD) patients may have a different iron metabolism compared to hemodialysis (HD) patients. This study aims to compare both dialysis modalities regarding their differences in iron management.</p><p><strong>Methods: </strong>PubMed (MEDLINE) and Embase were screened for randomized controlled trials and observational studies including both patients on HD or PD with information on iron management. Outcomes for iron management for this systematic review included: prevalence of supplementation, route of administration, dose, frequency and hemoglobin and iron status parameters.</p><p><strong>Results: </strong>15 eligible studies (930,436 patients), of which 8 cohort and 7 cross-sectional, were analyzed. The prevalence of intravenous (IV) iron supplementation ranged from 11.7% to 84.4% in HD patients, compared to 1.6% to 49.0% in PD patients. Ten studies reported that HD patients only received IV iron, while five studies reported this for PD patients. For oral iron supplementation, three studies involved HD patients, whereas seven studies involved PD patients. The cumulative monthly IV iron dose ranged from 108 to 750 mg in the HD group, compared to 65 to 250 mg in the PD group. Hemoglobin levels ranged from 10.0 to 12.0 g/dL in HD patients, versus 9.6 to 11.9 g/dL in PD patients.</p><p><strong>Conclusion: </strong>Iron management differs between HD and PD patients, with HD patients receiving higher doses and more frequent IV iron. There was significant heterogeneity in the outcomes between the studies, primarily due to the lack of a uniform global policy on iron management. Despite these differences, hemoglobin levels and iron status parameters were comparable between the two groups. Future research should explore the underlying mechanisms and broader impacts of iron treatment, including patient-reported outcomes, to optimize anemia management and improve quality of life for dialysis patients.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42022336970.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1488758"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analyzing body composition in living kidney donors: impact on post-transplant kidney function.
Frontiers in nephrology Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1467669
Evelien E Quint, Lisa B Westenberg, Gertrude J Nieuwenhuijs-Moeke, Eva A N van den Broek, Marcel Zorgdrager, Alain R Viddeleer, Stephan J L Bakker, Ija M Nolte, Marco van Londen, Robert A Pol
{"title":"Analyzing body composition in living kidney donors: impact on post-transplant kidney function.","authors":"Evelien E Quint, Lisa B Westenberg, Gertrude J Nieuwenhuijs-Moeke, Eva A N van den Broek, Marcel Zorgdrager, Alain R Viddeleer, Stephan J L Bakker, Ija M Nolte, Marco van Londen, Robert A Pol","doi":"10.3389/fneph.2024.1467669","DOIUrl":"10.3389/fneph.2024.1467669","url":null,"abstract":"<p><p>Living donor kidney transplantation boasts superior patient and graft survival rates compared to deceased donor kidney transplantation. However, the impact of living donor body composition (BC) on post-transplant kidney function remains uncertain. In a cohort of 293 living kidney donor-recipients pairs, we utilized linear mixed model analyses, adjusted for time and including a multiplicative interaction term of time with the donor body composition measure, and found no significant associations between any donor BC measure and the annual change in recipient post-transplantation estimated glomerular filtration rate (eGFR) [donor body mass index (BMI): <i>B</i>=-0.01, 95%CI -0.13; 0.11, <i>p</i>=0.88; donor waist circumference: <i>B</i>=0.02, 95%CI -0.02; 0.06, <i>p</i>=0.38; donor skeletal muscle index: <i>B</i>=-0.02, 95%CI -0.07; 0.04, <i>p</i>=0.63; donor skeletal muscle radiation attenuation: <i>B</i>=-0.002, 95%CI -0.06; 0.06, <i>p</i>=0.96; donor visceral adipose tissue index: <i>B</i>=-0.001, 95%CI -0.02; 0.02, <i>p</i>=0.93; donor subcutaneous adipose tissue index: <i>B</i>=-0.001, 95%CI -0.02; 0.02, <i>p</i>=0.94; donor intramuscular adipose tissue index: <i>B</i>=-0.12, 95%CI -0.29; 0.06, <i>p</i>=0.19; donor total abdominal adipose tissue index: <i>B</i>=-0.001, 95%CI -0.01; 0.01, <i>p</i>=0.89]. Our study suggests that pre-donation BC does not affect post-transplantation recipient eGFR in donor populations with a BMI below 35 kg/m<sup>2</sup>.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1467669"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possible benefits for environmental sustainability of combined therapy with hemodialysis and peritoneal dialysis in Japan.
Frontiers in nephrology Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1394200
Kei Nagai
{"title":"Possible benefits for environmental sustainability of combined therapy with hemodialysis and peritoneal dialysis in Japan.","authors":"Kei Nagai","doi":"10.3389/fneph.2024.1394200","DOIUrl":"10.3389/fneph.2024.1394200","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1394200"},"PeriodicalIF":0.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nephrology intervention to avoid acute kidney injury in patients awaiting cardiac surgery: randomized clinical trial. 为避免心脏手术候诊患者急性肾损伤而进行的肾脏病干预:随机临床试验。
Frontiers in nephrology Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1470926
Sergi Codina, Laia Oliveras, Eva Ferreiro, Aroa Rovira, Ana Coloma, Nuria Lloberas, Edoardo Melilli, Miguel Hueso, Fabrizio Sbraga, Enric Boza, José M Vazquez, José L Pérez-Fernández, Joan Sabater, Josep M Cruzado, Nuria Montero
{"title":"Nephrology intervention to avoid acute kidney injury in patients awaiting cardiac surgery: randomized clinical trial.","authors":"Sergi Codina, Laia Oliveras, Eva Ferreiro, Aroa Rovira, Ana Coloma, Nuria Lloberas, Edoardo Melilli, Miguel Hueso, Fabrizio Sbraga, Enric Boza, José M Vazquez, José L Pérez-Fernández, Joan Sabater, Josep M Cruzado, Nuria Montero","doi":"10.3389/fneph.2024.1470926","DOIUrl":"10.3389/fneph.2024.1470926","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-known complication that increases morbidity and mortality rates. The objective of this study was to reduce CSA-AKI through nephrologist intervention in patients awaiting cardiac surgery.</p><p><strong>Methods: </strong>We performed a single center, open-label, randomized clinical trial including 380 patients who underwent scheduled cardiac surgery at the Hospital de Bellvitge between July 2015 and October 2019. A total of 184 patients were evaluated by the same Nephrologist one month before the surgery to minimize the risk factors for AKI. In addition to assessments at the outpatient clinic, we also collected clinical data during hospitalization and during the first year.</p><p><strong>Results: </strong>Despite the intervention, no differences were observed between the groups in the incidence of CSA-AKI (intervention group 26.37% vs. standard of care 25.13%, p=0.874), mortality (3.91% vs. 3.59%, p=0.999), length of Intensive Care Unit (ICU) stay (10 days [7.00;15.0] for both groups, p=0.347), or renal function after one year of follow-up (estimated glomerular filtration rate (eGFR) by CKD-EPI: 74.5 ml/min (standard deviation 20.6) vs 76.7 (20.8) ml/min, respectively, p=0.364). A reduction in the need for blood transfusion was observed in the intervention group, although the difference was not statistically significant (37.22% vs. 45.03%, p =0.155).</p><p><strong>Conclusion: </strong>In this clinical trial, nephrologist intervention in the entire population on the cardiac surgery waiting list did not show a nephroprotective benefit.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, identifier (NCT02643745).</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1470926"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing global and regional public interest in home dialysis modalities from 2004 to 2024. 评估 2004 至 2024 年全球和地区公众对家庭透析方式的兴趣。
Frontiers in nephrology Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1489180
Charat Thongprayoon, Wannasit Wathanavasin, Supawadee Suppadungsuk, Paul W Davis, Jing Miao, Michael A Mao, Iasmina M Craici, Fawad Qureshi, Wisit Cheungpasitporn
{"title":"Assessing global and regional public interest in home dialysis modalities from 2004 to 2024.","authors":"Charat Thongprayoon, Wannasit Wathanavasin, Supawadee Suppadungsuk, Paul W Davis, Jing Miao, Michael A Mao, Iasmina M Craici, Fawad Qureshi, Wisit Cheungpasitporn","doi":"10.3389/fneph.2024.1489180","DOIUrl":"10.3389/fneph.2024.1489180","url":null,"abstract":"<p><strong>Background and objectives: </strong>Home dialysis (peritoneal dialysis and home hemodialysis) is an important renal replacement therapy modality option for patients with end-stage kidney disease. As the Internet has become a primary source for healthcare information, this study aimed to analyze the global and regional interests in home dialysis using Google Trends™ data from January 2004 to March 2024.</p><p><strong>Design setting participants and measurements: </strong>A comprehensive analysis was conducted using Google Trends™ with the search terms \"Peritoneal Dialysis\" and \"Home Hemodialysis.\" This study extracted worldwide trends and detailed regional interests within the United States. Interest levels were quantitatively assessed based on Google Trends™ indices, providing insights into temporal patterns and geographical distributions of public interest.</p><p><strong>Results: </strong>The study found a fluctuating pattern of global interest in Peritoneal Dialysis, with peak interest in March 2022 and lowest interest in December 2008. The most recent data from March 2024 showed significant interest level of 94, indicating a new upward trend. Mexico exhibited the highest relative interest in Peritoneal Dialysis. Within the United States, Tennessee demonstrated the highest interest. For Home Hemodialysis, the peak interest was in July 2004. The most recent data from March 2024 showed a modest increase in interest. The United States led in highest relative interest for Home Hemodialysis, followed by Australia, Canada, and the United Arab Emirates. Within the United States, Mississippi demonstrated the highest interest.</p><p><strong>Conclusions: </strong>This study offers crucial insights into the global and regional landscape of interest in home dialysis modalities over time, highlighting the significance of leveraging online platforms to increase public awareness, education, and engagement home dialysis modalities. By understanding the temporal and geographical patterns of interest, healthcare providers, policymakers, and patient advocacy groups can develop targeted strategies to better promote the benefits of home dialysis, address knowledge gaps, and improve access to these life-sustaining treatments.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1489180"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triple monoclonal protein-related kidney lesions in a patient with plasma cell dyscrasia: a case report. 一名浆细胞发育不良患者的三重单克隆蛋白相关肾脏病变:病例报告。
Frontiers in nephrology Pub Date : 2024-11-08 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1399977
Arsalan Alvi, Alexander J Gallan, Nattawat Klomjit
{"title":"Triple monoclonal protein-related kidney lesions in a patient with plasma cell dyscrasia: a case report.","authors":"Arsalan Alvi, Alexander J Gallan, Nattawat Klomjit","doi":"10.3389/fneph.2024.1399977","DOIUrl":"10.3389/fneph.2024.1399977","url":null,"abstract":"<p><p>A toxic monoclonal protein typically results in a single kidney pathology due to the specific biophysical characteristics of monoclonal proteins. Multiple monoclonal protein lesions are rarely reported and often portend a poor prognosis. We present a 57-year-old male who developed rapidly progressive glomerulonephritis after concealed ruptured diverticulitis. A kidney biopsy showed light chain cast nephropathy, light chain proximal tubulopathy, and thrombotic microangiopathy. Laboratories showed IgG kappa with an M-spike of 0.2 g/dl and a kappa light chain of 16 mg/dl. A bone marrow biopsy showed 3% kappa-restricted plasma cells. The dramatic renal presentation despite the minimal hematological burden is suggestive of a highly toxic light chain, which is consistent with monoclonal gammopathy of renal significance (MGRS). Clone-directed therapy and a complement blockade were initiated. The patient remained dialysis-dependent despite a hematological response. This case highlights the importance of considering the toxic properties of monoclonal proteins in causing kidney diseases. Our case is the first report of an MGRS patient with three distinct kidney lesions. Triple monoclonal protein-related kidney lesions are very rare and are usually associated with multiple myeloma. Light chain cast nephropathy (LCCN) is a myeloma-defining event but his light chain (LC) (<50 mg/dl) and plasma cell (<10%) burdens were low which makes this case very unusual. Sepsis-induced low-flow stage and the toxic properties of LC may induce LCCN in this patient. Aggressive therapy is likely needed to eradicate the clone in order to achieve an organ response.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1399977"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary: Obstructive sleep apnea in the hemodialysis population: are clinicians putting existing scientific evidence into practice? 评论:血液透析人群中的阻塞性睡眠呼吸暂停:临床医生是否将现有科学证据付诸实践?
Frontiers in nephrology Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1450204
Aleena Jamal, Som P Singh, Fawad Qureshi
{"title":"Commentary: Obstructive sleep apnea in the hemodialysis population: are clinicians putting existing scientific evidence into practice?","authors":"Aleena Jamal, Som P Singh, Fawad Qureshi","doi":"10.3389/fneph.2024.1450204","DOIUrl":"10.3389/fneph.2024.1450204","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1450204"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of fibrinogen levels in sepsis-associated acute kidney injury: unveiling a nonlinear relationship and clinical implications. 脓毒症相关急性肾损伤中纤维蛋白原水平的预后意义:揭示非线性关系和临床意义。
Frontiers in nephrology Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI: 10.3389/fneph.2024.1398386
Manqin Chen, Xinbin Chen, Huaxiang Ling, Chengwen Bai, Lihua Chen, Lin Zhong, Ping Gong, Fei Shi
{"title":"Prognostic significance of fibrinogen levels in sepsis-associated acute kidney injury: unveiling a nonlinear relationship and clinical implications.","authors":"Manqin Chen, Xinbin Chen, Huaxiang Ling, Chengwen Bai, Lihua Chen, Lin Zhong, Ping Gong, Fei Shi","doi":"10.3389/fneph.2024.1398386","DOIUrl":"10.3389/fneph.2024.1398386","url":null,"abstract":"<p><strong>Background: </strong>Fibrinogen plays a pivotal role in the inflammatory cascade and is intricately linked to the pathogenesis of sepsis. Nevertheless, its significance as a prognostic marker for sepsis-associated acute kidney injury (SA-AKI) remains uncertain. This study aimed to investigate the association between fibrinogen levels and 28-day mortality with sepsis-associated acute kidney injury.</p><p><strong>Method: </strong>The fibrinogen levels of patients admitted to the intensive care unit of Beth Israel Deaconess Medical Center between 2008 and 2019 were retrospectively assessed, and those diagnosed with SA-AKI were divided into low, middle and high fibrinogen level groups according to tertiles. Multivariate Cox proportional hazards model was used to assess the 28-day mortality risk of the SA-AKI patients.</p><p><strong>Results: </strong>A total of 3,479 patients with SA-AKI were included in the study. Fibrinogen demonstrated an independent association with 28-day mortality, yielding a hazard ratio (HR) of 0.961 (95% confidence interval [CI]: 0.923-0.999, <i>P</i> = 0.0471). Notably, a non-linear relationship between fibrinogen levels and 28-day mortality was observed, with the threshold observed at approximately 1.6 g/l. The effect sizes and corresponding CIs below and above this threshold were 0.509 (0.367, 0.707) and 1.011 (0.961, 1.064), respectively. Specifically, the risk of mortality among SA-AKI patients decreased by 49.1% for every 1 g/l increment in fibrinogen, provided that fibrinogen levels were less than 1.6 g/l.</p><p><strong>Conclusion: </strong>In patients with SA-AKI, a non-linear relationship was identified between fibrinogen levels and 28-day mortality. Particularly, when their fibrinogen levels were less than 1.6 g/l, a concomitant decrease in 28-day mortality was observed as fibrinogen levels increased.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1398386"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信